Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod

A key health ministry panel on April 25 recommended approval for AstraZeneca’s PD-L1 inhibitor durvalumab, otherwise known as Imfinzi, for the treatment of stage III non-small cell lung cancer (NSCLC). An official stamp of approval is expected for June, if...read more